Skip to main content
  • Clinical Trials
  • askSARAH
  • Blog
  • Find a Location
  • Careers
×
Recent Searches
    Cancer Questions?
    • Home
    • Who We Are

      Who We Are

      • About Us
      • Band Against Cancer
      • Careers
      • Connect With Us
      • History
      • Donate
      • News
      • Leadership
      • Mission
      • Sarah Cannon: The Name
      • Scientific Meetings
    • Why Choose Us

      Why Choose Us

      • Accreditations & Quality
      • Centers of Excellence
      • Clinical Safety
      • Contract Research Organization
      • Drug Development Program
      • Ethics and Compliance
      • Our Oncology Focus
      • Oncology Strategic Sites
      • Site Management Organization
      • Why Sarah Cannon?
    • Services

      Services

      • Cancer Care Overview
      • Cardiovascular Research
      • Contract Research Organization
      • Nurse Navigators
      • Oncology Research
      • Personalized Medicine
      • Radiation Oncology
      • Sarah Cannon Transplant and Cellular Therapy Network
      • Site Management Organization
    • For Patients

      For Patients

      • Learn About Cancer - By Type
      • Immunotherapy
      • Nurse Navigators
      • Patient Stories
      • Sarah Cannon Expert Blog
      • What is askSARAH?
    • Clinical Trials

      Clinical Trials

      • Search Clinical Trials
      • What is a Clinical Trial?
    • Find A Doctor
    • Clinical Trials
    • askSARAH
    • Blog
    • Find a Location
    • Careers
    • Clinical Trials
    • askSARAH
    • Blog
    • Find a Location
    • Careers
    ×
    Recent Searches
      Sarah Cannon
      ×
      Recent Searches Clear
        Search
        Sarah Cannon
        ×
        Recent Searches Clear
          Search
          Sarah Cannon
          ×
          Recent Searches
            Cancer Questions?
            Cancer Questions?
            • Home
            • Who We Are

              Who We Are

              • About Us
              • Band Against Cancer
              • Careers
              • Connect With Us
              • History
              • Donate
              • News
              • Leadership
              • Mission
              • Sarah Cannon: The Name
              • Scientific Meetings
            • Why Choose Us

              Why Choose Us

              • Accreditations & Quality
              • Centers of Excellence
              • Clinical Safety
              • Contract Research Organization
              • Drug Development Program
              • Ethics and Compliance
              • Our Oncology Focus
              • Oncology Strategic Sites
              • Site Management Organization
              • Why Sarah Cannon?
            • Services

              Services

              • Cancer Care Overview
              • Cardiovascular Research
              • Contract Research Organization
              • Nurse Navigators
              • Oncology Research
              • Personalized Medicine
              • Radiation Oncology
              • Sarah Cannon Transplant and Cellular Therapy Network
              • Site Management Organization
            • For Patients

              For Patients

              • Learn About Cancer - By Type
              • Immunotherapy
              • Nurse Navigators
              • Patient Stories
              • Sarah Cannon Expert Blog
              • What is askSARAH?
            • Clinical Trials

              Clinical Trials

              • Search Clinical Trials
              • What is a Clinical Trial?
            • Find A Doctor
            • Clinical Trials
            • askSARAH
            • Blog
            • Find a Location
            • Careers
            loading, please wait

            More quick links

            Sarah Cannon Cancer Institute at HealthONE

            About Sarah Cannon Research Institute at HealthONE

            Sarah Cannon Research Institute at HealthONE offers the latest therapies through clinical trials to patients in our community. Through Sarah Cannon, we are a part of a network that has conducted community-based clinical trials for more than 20 years and 600+ first-in-man clinical trials to date. Sarah Cannon Research Institute has been a clinical trial leader in most approved cancer therapies over the last 10 years. The Sarah Cannon Research Institute at HealthONE Drug Development Unit (DDU) offers oncology clinical trials at the earliest phases of research and was designed to meet the specialized needs of patients seeking advanced cancer treatment options.

            Our Integrated Care

            Together, Sarah Cannon Research Institute and HealthONE offer integrated cancer services and treatment options to patients across the Rocky Mountain region. Through our partnership, we pair cutting-edge clinical cancer research with state-of-the-art technology to enhance the lives of cancer patients.

            Our Philosophy

            Participation in a clinical trial is the first step in fighting cancer, not the last.®

            At Sarah Cannon Research Institute at HealthONE, we believe clinical trials are a source of inspiration and a catalyst for hope. Our experienced team is committed to delivering the highest quality care, personalized attention and revolutionary technology to provide patients with access to promising and innovative clinical trials in Denver. Want to learn more about HealthONE’s partnership with Sarah Cannon? Find out more below.

            Our Team

            Clinicians

            • Gerald S. Falchook, MD – Director, Drug Development
            • Michael L. Pearlman, MD, PhD -- Neuro-Oncology
            • Manojkumar Bupathi, MD, PhD -- Genitourinary Oncology
            • Jason Henry, MD -- Associate Director, DDU
            • Ryan M. Weight, DO, MS -- Medical Oncology

            Program Leaders

            • Kelly Mozzetta — Senior Program Manager
            • Yesenia Mastache — Clinic Manager

            For Patients

            The First Step

            Sarah Cannon Research Institute at HealthONE is determined to make a difference in the lives of our patients and so many others. We currently have clinical trials actively enrolling patients. If you are interested in finding out more information related to our clinical trials, please call: (720)-754-2610.

            Speak to Your Doctor

            If you are interested in participating in a clinical trial, contacting your doctor is the first step. We will coordinate with your doctor directly to see if you are a good fit for the trial. If you are eligible and choose to take part in a study, you may be able to receive new, cutting-edge treatment and help to improve the lives of future cancer patients.

            What to Expect

            • Experienced and personalized care from esteemed physicians and renowned leaders in cancer drug development
            • Innovative cancer treatment options close to home in Denver
            • Support from a passionate and caring team of medical professionals
            • Clear and open communication about clinical trial options
            • Personalized cancer treatment strategies through genomic tumor testing
            • Our facility, located on the Presbyterian St. Luke’s Medical Center campus, includes a clinic, an infusion center, an investigational pharmacy, a lab processing area and office space.

            Patient Testimonial- Erin Bond

            Partnerships

            Sarah Cannon Research Institute at HealthONE is part of Sarah Cannon, the Cancer Institute of HCA Healthcare. Together, Sarah Cannon and HealthONE offer integrated cancer services to communities across the greater Denver area and Rocky Mountain region, which can be accessed at the following HealthONE family of hospitals:

            • The Medical Center of Aurora
            • North Suburban Medical Center
            • Presbyterian/St. Luke's Medical Center
            • Rocky Mountain Blood and Marrow Transplant Program
            • Rocky Mountain Hospital for Children
            • Rose Medical Center
            • Sky Ridge Medical Center
            • Swedish Medical Center

            Through our partnership, we pair cutting-edge research with world-class cancer services that span the entire cancer care journey from diagnosis through survivorship.

            Contact Us

            Open Trials and Patient Referrals

            To view clinical cancer trials that are currently enrolling, click the link below. For more information about our current trials or for general inquiries, call us at (720)-754-2610.

            Contact Us: (720)-754-2610

            Sarah Cannon Research Institute at HealthONE
            1800 Williams Street
            Suite 300
            Denver, CO 80218

            Clinical Trials

            Open Clinical Trials

            NCT05614102

            An open-label, phase 1, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics, and tumor response profile of the diacylglycerol kinase zeta inhibitor (DGKzi) BAY 2965501 in participants with advanced solid tumors

            NCT05585034

            A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®808 in Combination with Pembrolizumab in Selected Advanced Solid Tumors

            NCT05578092

            A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway

            NCT05631327

            Phase 1, Open-Label, Dose-Finding, and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of JZP341 in Adult Participants With Advanced or Metastatic Solid Tumors

            NCT05268666

            A First-in-Human, Open-label, Dose Escalation and Expansion Study of Orally Administered JBI-802 in Patients with Advanced Solid Tumors

            NCT05241613

            A Phase I, Open-label, Multi-center, Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC176 in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Have Progressed on at Least Two Prior Systemic Therapies

            NCT05194072

            A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors

            NCT05256290

            A Phase 1 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung Cancer

            NCT05239143

            A PHASE 1 DOSE ESCALATION AND EXPANDED COHORT STUDY OF P-MUC1C-ALLO1 IN ADULT SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS

            NCT05070247

            NCT05159518

            A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT2527 in Patients with Advanced Solid Tumors

            NCT05070247

            An Open-label, Dose Escalation and Expansion, Phase 1a/1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors

            NCT04787042

            A PHASE 1A OPEN-LABEL, DOSE-ESCALATION, AND A PHASE 2 STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF ST-067 ADMINISTERED SUBCUTANEOUSLY AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY SOLID TUMORS

            NCT05080842

            A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC682 in Patients with Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

            NCT04972981

            A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients With Selected Advanced Solid Tumor

            NCT04029922

            A Phase 1b open-label, multicenter dose escalation and expansion study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors (Pro00051409)

            NCT04609579

            Phase 1 Open-label Study of SNX281 Given as Monotherapy and in Combination with a Checkpoint Inhibitor in Subjects with Advanced Solid Tumors and Lymphoma

            NCT04666688

            A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Antitumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Anti-PD-1 in Patients with Metastatic Solid Tumors

            NCT04587479

            A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-8263 in Adult Subjects with Advanced Solid Tumors

            NCT04622774

            A Phase 1, First-in-Human, Open-Label, Dose-Escalation Study of IMGC936 (Anti-ADAM9 Antibody Drug Conjugate) in Patients with Advanced Solid Tumors

            NCT04553692

            An Open-Label, Multicenter, Phase I Study of IGM-8444 as a Single Agent and in Combination with Chemotherapy-Based Regimens in Subjects with Relapsed and/or Refractory Solid Cancers

            NCT04089449

            A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of PRT811 in Subjects with Relapsed/Refractory Myelofibrosis, Advanced Solid Tumors and Recurrent High-Grade Gliomas

            NCT03752398

            A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects with Selected Advanced Solid Tumors (DUET-3)

            NCT03997968

            A Multi-Center, Open Label Phase 1/2 Study Of CYT-0851, An Oral RAD51 Inhibitor, In Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors

            NCT04045496

            A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients with Advanced Solid Tumors

            NCT03170960

            A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

            NCT03700294

            A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients with Advanced Solid Tumors

            NCT03440450

            A Phase 1 Dose-escalation Study of FF-10832 for the Treatment of Advanced Solid Tumors

            NCT03600883

            A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With a Specific KRAS Mutation

            NCT03518554

            A Phase 1, Multi-Center, Dose Escalation, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3068 in Adult Patients with Advanced Solid Tumors

            NCT03157128

            A Phase 1 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity

            NCT02720068

            A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

            NCT02383212

            A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies

            NCT03261947

            An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients with Metastatic Pancreatic Cancer or Metastatic Colorectal Cancer

            NCT03221400

            A Phase 1/2a, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of PEN-866 in patients with advanced solid malignancies

            NCT02795156

            A Phase II Study to Evaluate the Activity of Commercially Available Molecularly Matched Targeted Therapies in Selected Tumor Types Based on Genomic Alterations

            NCT02817633

            A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors

            NCT02661542

            A Phase 1/2a, dose-escalation study of FF-10502-01 for the treatment of advanced solid tumors and lymphomas

            NCT02549937

            A Multi-Center, Open-Label Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors

            NCT02579226

            A Phase I, Open-Label,Multicentre Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD2811 in Patients with Advanced Solid Tumours

            NCT02264613

            A Phase I Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 in Patients with Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein

            Phase Ib Study Evaluating the c-Met Inhibitor INC280 in Combination With Bevacizumab in Glioblastoma Multiforme (GBM), Metastatic Colorectal Cancer (mCRC) and Metastatic Renal Cell Carcinoma (mRCC) Patients

            Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies

            NCT03972657

            A Phase1/2 Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer

            NCT03250832

            A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors

            NCT0416139

            A phase 1/2 study of TPX-0046, a Novel Oral RET/SRC Inhibitor in Adult Subjects with Advanced/Mestatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations.

            NCT04047251

            Phase 1 study of FF-10850, topotecan liposome injection, in advanced solid tumors including ovarian and cervical carcinoma, sarcomas, and neuroendocrine tumors including small cell lung cancer

            NCT03967223

            Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1- Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NYESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

            NCT04145622

            Phase I/II, Two-Part, Multicenter First-in-Human Study of DS-7300a in Subjects with Advanced Solid Malignant Tumors

            NCT04148937

            A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Malignancies

            NCT04249947

            A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

            NCT04348916

            A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of ONCR-177, an Oncolytic Herpes Simplex Virus for Intratumoral Injection, Alone and in Combination with PD-1 Blockade in Adult Subjects with Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors

            NCT04528836

            A Phase 1/1B First-in-Human Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in Patients with Advanced Solid Tumors

            Learn the importance of clinical trials
            Learn the importance of clinical trials
            Clinical Trials
            Have Cancer Questions?<br>Call askSARAH
            Have Cancer Questions?
            Call askSARAH
            Cancer Questions?
            Sarah Cannon Center for Blood Cancer
            Sarah Cannon Center for Blood Cancer
            Blood Cancer
            Sarah Cannon Cancer Care at HealthONE
            Sarah Cannon Cancer Care at HealthONE
            Cancer Care

            Locations

            loading, please wait

            Retrieving location data...
            Use my location
              Or Use My Location

              List Map

              Facility Star Rating Description

              Each patient’s experience at our practice is important to us. As we strive to provide the highest level of care, we value feedback on all aspects of the patient experience. This Medical GPS patient experience survey measures patient satisfaction from the time the appointment was made to the time the patient spent with the provider.

              • Recommend: The Recommendation rating reflects patients’ overall likelihood of recommending their provider to friends or family members.
              • Exam Thorough: The Exam Thorough rating reflects how satisfied patients were at the thoroughness and completeness of their examination and treatment.
              • Provider Answers: The Provider Answers rating shows the level of patient satisfaction on how the provider was able to answer questions and fully explain treatment.
              • Provider Concern: Provider concern measures the extent to which patients agree they were treated with courtesy, respect and concern throughout the entire examination.
              • Wait Reasonable: This rating measures patient satisfaction on the total time spent waiting for the provider.

              Your Destination

              Sarah Cannon

              Sarah Cannon
              1100 Dr. Martin L. King Jr. Blvd.
              Suite 800
              Nashville, TN 37203

              Main Number: (615) 329-7274

              Helpful Links

              • Who We Are
              • Why Choose Us
              • Services
              • For Patients
              • Clinical Trials
              • Our Locations

              Helpful Links

              • About Us
              • Cancer Expert Blog
              • Find a Location
              • Leadership
              • Careers
              • askSARAH
              • Band Against Cancer
              • Contact Us

              Follow Us

              Follow us on Facebook Follow us on Instagram Follow us on LinkedIn Follow us on Twitter
              Sarah Cannon

              Sarah Cannon
              1100 Dr. Martin L. King Jr. Blvd.
              Suite 800
              Nashville, TN 37203

              Main Number: (615) 329-7274

              Follow us on Facebook Follow us on Instagram Follow us on LinkedIn Follow us on Twitter
              Copyright 1999-2023 C-HCA, Inc.; All rights reserved.
              Terms & Conditions | California Notice at Collection | Privacy Policy
              Social Media Policy | Acceptable Use Policy | HCA Nondiscrimination Notice
              Surprise Billing Protections | Right to Receive Estimate | Accessibility | Disclosures
              Copyright 1999-2023 C-HCA, Inc.; All rights reserved.
              Terms & Conditions | California Notice at Collection | Privacy Policy
              Social Media Policy | Acceptable Use Policy | HCA Nondiscrimination Notice
              Surprise Billing Protections | Right to Receive Estimate | Accessibility | Disclosures